No profile data available.
LivaNova PLC (LIVN) is a healthcare company in the heart treatment equipment industry, based in Gloucester, United Kingdom, with about 3,300 full-time employees.
It reported revenue of $1.39 billion for fiscal year 2025, up 10.7% from fiscal year 2024, and net income of -$242.47 million. Its largest business segment, Cardiopulmonary, brought in 57% of segment revenue in fiscal year 2025; United States was the largest region with 53%. Its market capitalization was $4.21 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation.
LivaNova reported $1.39 billion in revenue for fiscal year 2025, up 10.7% from $1.25 billion in fiscal year 2024.
Cardiopulmonary, with $785.39 million or 57% of segment revenue in fiscal year 2025. Next: Neuromodulation (43%) and Other (1%).
United States: 53% of revenue by region in fiscal year 2025, followed by Rest of World (27%).
$4.21 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (heart treatment equipment) include Edwards Lifesciences Corporation (EW), Heartflow, Inc. (HTFL), Pulse Biosciences, Inc. (PLSE), iRhythm Technologies, Inc. (IRTC).